Close to 80% of what influences how long someone is going to live is where and how they live, and we need to pay more attention to that or we’re not paying attention to everything that affects their lives, explained David A. Eagle, MD, of New York Cancer & Blood Specialists.
Close to 80% of what influences how long someone is going to live is where and how they live, and as community oncologists, we need to pay more attention to that or we’re not paying attention to everything that affects their lives, explained David A. Eagle, MD, of New York Cancer & Blood Specialists.
Transcript
What are some of today’s most pressing issues in community oncology?
Health equity is the current issue. A lot of the challenge for oncologists is, where do we put our attention. I’m glad we’re going to put it toward health equity. We spend a lot of time focusing on the medical care of our patients—which is incredibly important—but if you want to predict how long somebody is going to live, about 80% of that is where they live and how they live and not the medical care they receive. So we need to pay more attention to that. If we don’t pay attention to that, we’re not paying attention to everything that affects their lives.
I think one thing that we need to figure out in the oncology community is how to go from a reactive model to a proactive model. We need to figure out how to screen people at the very beginning of their health care journey about what their needs are, where the gaps are, and not wait until we hear about problems.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More